ストックスクリーナーアプリを入手
24.88
1.39%
0.34
Pfizer Inc (PFE) 最新ニュース
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
2nd Circ. Backs Ex-Pfizer Worker's Insider Trading Conviction - Law360
Vitiligo Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotech - Barchart.com
Pfizer: Still A Bargain Despite Kennedy's Anti-Vaccine Attacks (NYSE:PFE) - Seeking Alpha
Pfizer and BioNTech: Slightly Lowering Our MRNA Vaccine Forecast Due to US Policy Headwinds - Morningstar
Down 34%, Should You Buy the Dip on Viking Therapeutics? - The Motley Fool
Alopecia Market Key Players AnalysisPfizer, Inc., Lilly, Lexington Intl., LLC, Freedom Laser Therapy, Curallux. - openPR.com
Is Pfizer Inc. reversing from oversold territoryWeekly Profit Recap & Verified Technical Trade Signals - Newser
Pfizer's Diverse Portfolio Supports a Narrow Moat, Despite Patent Loss Headwinds - Morningstar
Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity? - sharewise.com
Pfizer Inc. (NYSE:PFE) Q1 2025 Earnings Call Transcript - MSN
Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer - Yahoo Finance
B-cell Lymphoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Biegene, Oncternal Therapeutics, Inc, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc - Barchart.com
How Pfizer Inc. (PFE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (September 2025) - 24/7 Wall St.
Type 1 Diabetes Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer - Barchart.com
Antimicrobial Therapeutics Market to Witness Massive Growth - openPR.com
3 Things You Need to Know if You Buy Pfizer Today - The Globe and Mail
Stock Analysis | Pfizer OutlookNavigating Volatility Amid Mixed Signals - AInvest
Global Vaccines Market is expected to reach US$ 108.82 billion - openPR.com
Eye Health Supplements Market Rocketing by 2032 with Industry - openPR.com
Pfizer CEO is latest to say Trump should get Nobel Peace Prize – for something much of MAGA hates - AOL.com
Cassidy, Pfizer CEO: Trump worthy of Nobel prize for COVID vaccine - AOL.com
Pfizer collaboration with Olema may spark future bidding waranalyst - MSN
Trump "worthy of the Nobel Peace Prize" for COVID vaccines, Pfizer CEO says - Axios
Pfizer, Moderna, Novavax respond to Trump’s criticism of COVID shot success - Seeking Alpha
Pfizer, Moderna defend COVID vaccine effectiveness after Trump remarks - Reuters
Prostate Cancer Pipeline Analysi, 2025 by DelveInsight | Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Phar - Barchart.com
Pfizer responds to Trump’s call for Covid-19 vaccine data, says Operation Warp Speed deserves Nobel Peace Prize - News Channel 3-12
Pfizer defends COVID-19 vaccine effectiveness after Trump remarks - Reuters
Updated: Responding to Trump, Pfizer CEO Bourla stands by Covid-19 vaccine data - Endpoints News
Pfizer (PFE) Partners With Olema For New Metastatic Breast Cancer Study - simplywall.st
Pfizer Reaffirms Transparency Commitment On COVID-19 Vaccine Data - Nasdaq
Pfizer Defends Covid Shot, Says Trump Deserves Nobel Prize - Yahoo Finance
Pfizer to Continue Disclosing Research Analysis of COVID-19 Vaccine; Calls Operation Warp Speed 'Success' - MarketScreener
Pfizer Defends Covid Vaccine Transparency in Response to Trump - Bloomberg
Pfizer defends Covid-19 vaccine transparency in response to Trump - The Edge Malaysia
Pfizer reaffirms commitment to COVID-19 vaccine transparency - Investing.com
Pfizer : Responds to Success of Operation Warp Speed and Reaffirms Transparency of COVID Vaccine Data - MarketScreener
Pfizer says it will soon share new data on latest vaccine strain which FDA approved - MarketScreener
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
Pfizer (PFE) Volatility and Risk Allocation: Navigating a Shifting Pharmaceutical Landscape - AInvest
Pfizer's Strategic Reinvention: Execution Discipline and Risk Allocation Reshape Valuation Narrative - AInvest
What are Pfizer Inc.’s earnings expectationsMarket Performance Report & Low Drawdown Investment Ideas - خودرو بانک
Pfizer's Strategic Volatility: Tactical Entry Points and Rule-Based Trading in a Biotech Recovery - AInvest
Pfizer's Strategic Volatility: Decoding Recent Share Price Swings and Tactical Entry Points - AInvest
Pfizer's Surging Momentum: A Catalyst for Large-Cap Biotech Growth - AInvest
$33M Pfizer Antitrust Deal OK'd, First MDL Trial Date Set - Law360
Pfizer's Golden Cross and Pipeline Progress: A Dividend-Driven Turnaround or a Value-Trap Mirage? - AInvest
Pfizer's Pipeline Monetization and 7% Yield: A Dual-Engine Opportunity in a Re-Rating Pharma Landscape - AInvest
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Pfizer Defends Transparency On COVID-19 Vaccine Data, Says Trump’s ‘Operation Warp Speed’ Effort Deserves Nobel Peace Prize - Stocktwits
Backtesting results for Pfizer Inc. trading strategiesTrade Risk Report & Safe Entry Trade Signal Reports - Newser
Can Pfizer Inc. recover in the next quarterTrade Signal Summary & Daily Chart Pattern Signal Reports - Newser
Olema stock jumps after new clinical trial collaboration with Pfizer - Investing.com
Pfizer: Pipeline Monetization Shows Great PromiseRich Yields Pending Re-Rating (NYSE:PFE) - Seeking Alpha
Is Pfizer Stock Underperforming The Nasdaq? - Barchart.com
How One Woman with Multiple Myeloma Found Strength—and Gratitude—in Adversity - Pfizer
Olema Pharmaceuticals, Pfizer Collaborate for Clinical Trial of Breast Cancer Treatment - MarketScreener
Olema Pharmaceuticals Partners with Pfizer for New Trial - TipRanks
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer - The Manila Times
Pfizer, Moderna in focus as Trump demands answers on COVID success - Seeking Alpha
2.02%
1.62%
大文字化:
|
ボリューム (24 時間):